Objective: Endovascular aneurysm repair (EVAR) with percutaneous femoral access (PEVAR) has several potential advantages. Morbidly obese (MO) patients present unique anatomical challenges and have not been specifically studied. This study examines the trends in the use of PEVAR and its surgical outcomes compared with open femoral cutdown (CEVAR) in MO patients. The PEVAR group included any remaining patients who had only codes for EVAR and endovascular procedures. Linear correlation was used to evaluate temporal trends in the use of PEVAR among MO patients. Baseline comorbidities and surgical outcomes were compared between the PEVAR and CEVAR groups using c 2 tests or t-tests.
Since the introduction of endovascular aortic aneurysm repair (EVAR) for infrarenal abdominal aortic aneurysms (AAAs), patient and surgeon preferences have shifted greatly toward EVAR over the traditional open surgical approach. 1, 2 Percutaneous access for EVAR (PEVAR), whereby a closure device is used to close large access site femoral arteriotomies rather than directly exposing the vessel with cutdown (CEVAR), also has become more popular since its initial description in 1999. 3 Numerous retrospective reviews and several randomized trials have reported the advantages of PEVAR compared with CEVAR, including reductions in operative time, time of anesthesia, [4] [5] [6] [7] [8] [9] [10] hospital length of stay, 5, 9, 11, 12 and access site and wound complications. 4, [6] [7] [8] [9] [11] [12] [13] Most recently a large-scale retrospective review of a national database of 4112 patients showed shorter operative time, length of stay, and fewer wound complications for those undergoing PEVAR. 14 Recent studies have also examined EVAR in general with regards to its use in obese patients and found higher rates of wound complications and mortality for obese compared with nonobese patients. 15, 16 However, there are currently no studies that have specifically examined the use of PEVAR in morbidly obese (MO) patients. These patients may present unique anatomic challenges for closure device use and Table II , online only). Patients were included in the CEVAR group if they had any one of these 11 selected CPT codes.
The analysis excluded patients with additional codes indicating further complex endovascular or open procedures that would potentially add operative time, blood loss, morbidity, and recovery time unrelated to the primary operation of infrarenal EVAR. Briefly, these included procedures such as endovascular visceral artery interventions, infrainguinal bypasses, and iliac conduits for EVAR. The PEVAR group included any remaining patients who had only CPT codes for EVAR and related endovascular procedures.
As noted, patients in the Targeted Vascular data set for 2011 to 2013 could be determined to have PEVAR or CEVAR based on the access variable. To examine the possible effects of failed PEVAR converted to CEVAR in confounding the analysis, the relative frequencies of each access approach were analyzed for the patients of the Targeted Vascular data set for 2011 to 2013.
Clinical variables and outcomes. The temporal trend in the total EVAR procedures and the proportion performed percutaneously were reported between 2005/ 2006 and 2013. Baseline data including BMI, age, diabetes, smoking, chronic obstructive pulmonary disease (COPD), congestive heart failure, dialysis dependence, history of stroke, history of myocardial infarction (MI), history of need for revascularization for peripheral artery disease, and EVAR performed as an emergency were analyzed and compared between PEVAR and CEVAR groups.
Postoperative outcomes available in the NSQIP database, including 30-day mortality, wound complications (disruption, superficial/deep surgical site infection [SSI], organ space infection), unplanned intubation, pulmonary embolism, deep vein thrombosis, MI, duration of anesthesia, total operation time, and hospital length of stay, were also compared between groups. Subgroup analysis of the variables and outcomes was also performed for superobese patients, defined as having BMI $50 kg/m 2 .
Statistical analysis. Frequencies of preoperative variables and clinical outcomes between groups receiving CEVAR vs PEVAR were compared using c 2 or Fisher exact tests for categoric variables. Differences in continuous variables were evaluated using two-sample t-tests. Baseline characteristics. There were 27,946 patients who underwent EVAR, of which 833 (3.0%) were MO. Of these, 470 patients (56.4%) were categorized to the CEVAR group and 363 (43.6%) to the PEVAR group. The baseline demographic and comorbidity characteristics associated with all patients are summarized in Table I . A statistically significant difference was noted between the CEVAR and PEVAR groups only for history of severe COPD (29.6% CEVAR vs 22.6% PEVAR; P ¼ .024). There was no difference between groups in the use of steroids for chronic conditions (P ¼ .339). The groups were otherwise similar with respect to comorbidities, including age, BMI, diabetes, congestive heart failure, history of stroke or MI, current dialysis dependence, and smoking. There was no difference in the functional status of patients in both groups or in the frequency of emergency cases.
In a separate subgroup analysis of the Targeted Vascular data set for 2011 to 2013, groups of attempted PEVAR converted to CEVAR compared with successful PEVAR were created to investigate the consequences of failed PEVAR. For this data set, percutaneous procedures attempted in three of 44 PEVAR cases in MO patients were converted to CEVAR for a 6.81% conversion rate. Two PEVARs were performed in superobese patients, and none were converted to CEVAR (0% conversion). This sample was too small to perform a meaningful statistical analysis of characteristics and outcomes.
Outcomes. There was no difference in mortality between PEVAR (1.7%) and CEVAR (2.6%) in MO patients (P ¼ .376). The complication rates were similar, including MI (P ¼ .999) and pulmonary embolism (P ¼ .702). There was a trend toward decreased bleeding requiring transfusion in the PEVAR group, although this was not statistically significant (P ¼ .064). Regarding wound complications, individually graded complications, such as wound disruption, deep SSIs, superficial SSIs, and organ space SSIs, each showed no difference between groups. However, there was a decreased overall rate of wound complications in the PEVAR group (5.5% vs 9.4%, P ¼ .039). Difference in frequency of return to the operating room between the two groups was not statistically significant (P ¼ .532). CEVAR had statistically significant increase in mean duration of anesthesia times (260 minutes vs 244 minutes; P ¼ .048) and mean total operation time (174 minutes vs 158 minutes; P ¼ .002). There was also a nonsignificant trend toward PEVAR patients being more likely to be discharged home rather than to a facility (93.6% vs 87.8%; P ¼ .060). There was no difference in any other complication or mortality (Table II) .
There were 109 superobese patients (59 CEVAR and 50 PEVAR). Subgroup analysis showed no differences between the groups (Table III) .
DISCUSSION
Obesity is an epidemic problem in the United States, with most recent estimates showing 5.6% of Americans aged 20 to 39, 7.7% aged 40 to 59, and 5.6% aged $60 are MO. 19 As this obese population continues to age and grow in proportion, 20 The results of this study are consistent with a recently published retrospective study using the vascular data set of the ACS NSQIP targeting EVAR and comparing PEVAR and CEVAR in all patients. Buck et al 14 noted
significantly shorter mean length of stay and mean total operation time in patients undergoing PEVAR. Their study also showed a significant decrease in any wound complication. It is likely that MO patients would require more extensive incisions and dissection to achieve femoral artery exposure. Also, mobilizing these patients after surgery and caring for their wounds is more difficult, leading to increasing functional and mobility delays postoperatively with consequent morbidity and decreased rates of discharge home. For these patients, a successful percutaneous approach would accentuate the postoperative functional benefits. Although the exact cause may remain debatable, there appear to be consistent benefits for percutaneous access in both obese and nonobese patients, especially in terms of wound complications. Obesity as a predictor of outcome in EVAR has been studied in multiple settings recently. Saratzis et al 21 retrospectively compared perioperative outcomes in nonobese and obese patients undergoing EVAR and found no differences in survival and nonprocedurally related morbidity, defined as any type of major morbidity that was not directly related to the implant or the procedure, according to reporting standards published by Chaikof et al. 22 Park et al 16 both MO patients and non-MO patients. However, the two studies both show a temporal increase in the use of PEVAR and are consistent with it gaining wider popularity.
Previously published data regarding obesity as a factor in the technical success of PEVAR are inconsistent. Several studies have shown an association between obesity and technical failure, 7, 8, 23, 24 whereas at the same time, others have shown no association. 6, 13, 25, 26 One cannot draw any specific conclusions from this study about intraoperative technical success of PEVAR in MO patients because this outcome could not be directly recorded or inferred. Because the categorization of patients to the CEVAR group is determined by the presence or absence of any of the listed CPT codes related to femoral artery exposure, these data cannot be used to determine how many PEVAR attempts were converted to CEVAR or whether patients underwent unilateral or bilateral cutdowns. However, in the small subgroup analysis of access type frequencies in the Targeted Vascular dataset for 2011 to 2013, the 6.81% conversion rate to cutdown may suggest that the technical success of PEVAR in MO patients is relatively high. In any case, if PEVAR was performed successfully, which is assumed in this study from the absence of any femoral artery exposure codes, it does confirm benefits for PEVAR in total operative time and wound complications.
Despite conflicting data for the effect of obesity on the technical success of percutaneous access, there appears to be a growing preference among patients and surgeons to perform PEVAR instead of CEVAR in MO patients. Expanded surgeon experience with these procedures as well development of new lower-profile EVAR delivery systems will both likely lead to greater comfort and success in performing these techniques. Likewise, as the number of open AAA repairs continues to decline among vascular surgery trainees, it is equally conceivable that surgeons will continue to push the boundaries of endovascular techniques along with the published instructions for use of closure devices. 27 As devices continue to develop and indications and contraindications change, continuing to recognize and analyze their success and limitations within and outside of instructions for use will be important. As with all retrospective database studies, this study is vulnerable to several limitations. Most important, using CPT codes to categorize CEVAR and PEVAR patients is an indirect method of determining access and cannot delineate subtleties such as percutaneous converted to cutdown or unilateral cutdowns. In clinical practice, varying billing methods could lead to miss categorization of PEVAR cases into the CEVAR group and vice versa. In addition, although clinical abstractors for established databases like NSQIP are highly reliable, there may still be imperfections in charting and case review that could also lead to confounding in the analysis of patient characteristics and outcomes.
Despite these vulnerabilities, the large sample size obtained through the database strengthens this study by diluting the effect of outliers and record imperfections. Although the baseline characteristics reported here showed no significant differences except history of severe COPD, another potential limitation is that surgeon experience likely influenced the choice of treatment and the successful outcome for either approach. Furthermore, as noted previously, the actual technical success of PEVAR could not be inferred. Factors that have been reported to influence PEVAR success, such as use of ultrasound guidance, type of closure device, femoral artery calcification, vessel tortuosity, and groin scars, were not available in this database. 6, 24, 28, 29 Further prospective studies of PEVAR in MO patients will be required to control for these factors.
CONCLUSIONS
PEVAR is being increasingly used in MO patients and decreases wound complications compared with CEVAR. The results show a potential benefit for PEVAR in a larger cohort of MO and superobese patients than has been previously studied in the literature. In this age of increasing cost and resource-awareness in health care, reductions in wound complications and in any other complications become increasingly important. The results of this study and others emphasize the growing prevalence and value of PEVAR and the need for further development of this technique. 
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